Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.

Jun Li, Han Zhang, Peng Sun, Feng Gu, Zheli LiuPubMed 2013 · DOI

Abstract

Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
BibTeX
@inproceedings{li2013bevacizumab,
  author = {Jun Li and Han Zhang and Peng Sun and Feng Gu and Zheli Liu},
  title = {{Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.}},
  booktitle = {PubMed},
  year = {2013},
  doi = {10.3980/j.issn.2222-3959.2013.02.12},
}

Loading related content...

Figure